Wall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to Sell

Wall Street Zen downgraded shares of TScan Therapeutics (NASDAQ:TCRX - Free Report) from a hold rating to a sell rating in a research report released on Saturday morning.

Several other brokerages also recently issued reports on TCRX. Barclays cut their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Wedbush reissued an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Tuesday, May 6th. Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 price objective on shares of TScan Therapeutics in a report on Friday, March 14th. HC Wainwright dropped their target price on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Needham & Company LLC restated a "buy" rating and issued a $9.00 price target on shares of TScan Therapeutics in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat.com, TScan Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.80.

TScan Therapeutics Stock Performance

Shares of TCRX stock traded up $0.01 during trading on Friday, reaching $1.54. 450,410 shares of the company's stock were exchanged, compared to its average volume of 417,208. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $7.89. The firm's fifty day moving average price is $1.46 and its 200-day moving average price is $2.07. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $87.15 million, a PE ratio of -1.41 and a beta of 0.98.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.62 million. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. As a group, sell-side analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Activity

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of TScan Therapeutics stock in a transaction that occurred on Tuesday, May 20th. The shares were acquired at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the completion of the purchase, the insider now directly owns 7,946,141 shares of the company's stock, valued at $9,535,369.20. This represents a 17.79% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.35% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Prudential Financial Inc. bought a new stake in shares of TScan Therapeutics during the 4th quarter valued at approximately $32,000. ProShare Advisors LLC acquired a new stake in TScan Therapeutics in the fourth quarter valued at approximately $40,000. Hsbc Holdings PLC bought a new stake in shares of TScan Therapeutics during the first quarter worth $49,000. Wells Fargo & Company MN increased its holdings in shares of TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after buying an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of TScan Therapeutics during the fourth quarter worth $59,000. Institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.